, /PRNewswire/ -- Integral Molecular, a leader in providing essential research tools that enable vaccine development, proudly announces the achievement of ISO 9001 certification for the quality systems and processes used in their virology offerings. With over 20 years of experience and 100+ peer-reviewed publications in virology, Integral Molecular is a trusted partner for researchers and pharmaceutical companies worldwide, supplying critical reagents such as (RVPs), virus-like particles (VLPs), pseudoviruses, and Influenza TiterSafeTM VLPs. These non-replicative particles provide a ready-to-use substitute for live viruses and have been used in neutralization assays to support the clinical development of marketed vaccines.
ISO 9001 certification underscores Integral Molecular's commitment to maintaining the highest standards for quality. "The FDA has recognized the value of using non-replicative virus reagents to obtain immunogenicity data for vaccine studies—especially during the COVID pandemic, when the ability to conduct rapid serum neutralization studies was paramount. Our virology reagents are manufactured using standardized procedures and ISO-certified processes.
Scientists can trust the consistency and reliability of our products, knowing exactly what to expect each time." — Integral Molecular ( ) is the industry leader in creating and commercializing transformative technologies that advance the discovery of therapeutics against difficult protein targets. With 20+ .
